Status:
RECRUITING
Molecular and Cellular Basis of Severe Forms of Dengue in Sickle Cell Patients
Lead Sponsor:
Centre Hospitalier Universitaire de la Guadeloupe
Conditions:
Dengue (Virus); Fever, Sandfly
Sickle Cell Disease
Eligibility:
All Genders
6-25 years
Brief Summary
Dengue virus (DENV) belongs to the genus of Flavivirus transmitted by the mosquito Aedes aegypti and is responsible for an infectious disease associated with different forms and severities such as den...
Detailed Description
More precisely, the objective is to determine and compare the different cellular and molecular inflammatory mediators between SS and SC patients at baseline, and to study DENV-induced activation of va...
Eligibility Criteria
Inclusion
- patients with SS or SC SCD or controls with hemoglobin AA
- diagnosis of SCD performed by electrophoresis or HPLC in a reference laboratory for hemoglobinopathies
- patients older than 6 years and younger than 25 at inclusion
- clinically in a steady state at inclusion (without complication during the last month and without transfusion in the three last months)
- patients followed up for SCD at the sickle cell center of Guadeloupe (University hospital of Guadeloupe, Pointe-à-Pitre)
- patients or legal representatives of minors who will provide written informed consent in accordance with the Declaration of Helsinki
- patients affiliated to national social security
- the control group (AA subjects) will be recruited among volunteers recruited by posters
Exclusion
- patients with SS or SC SCD or controls with hemoglobin AA
- diagnosis of SCD performed by electrophoresis or HPLC in a reference laboratory for hemoglobinopathies
- patients older than 6 years and younger than 25 at inclusion
- clinically in a steady state at inclusion (without complication during the last month and without transfusion in the three last months)
- patients followed up for SCD at the sickle cell center of Guadeloupe (University hospital of Guadeloupe, Pointe-à-Pitre)
- patients or legal representatives of minors who will provide written informed consent in accordance with the Declaration of Helsinki
- patients affiliated to national social security
- the control group (AA subjects) will be recruited among volunteers recruited by posters
Key Trial Info
Start Date :
June 24 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 24 2026
Estimated Enrollment :
130 Patients enrolled
Trial Details
Trial ID
NCT07000747
Start Date
June 24 2024
End Date
June 24 2026
Last Update
June 3 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Chu de La Guadeloupe
Pointe-à-Pitre, Guadeloupe, 97159